Analysis of KRAS , NRAS , BRAF , PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analysis of
KRAS
,
NRAS
,
BRAF
,
PIK3CA
and
TP53
mutations in a large prospective series of locally advanced rectal cancer patients
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-14
DOI
10.1002/ijc.32507
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) R Glynne-Jones et al. ANNALS OF ONCOLOGY
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
- (2018) Maxime J M van der Valk et al. LANCET
- KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
- (2018) Francesco Sclafani et al. Scientific Reports
- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
- (2016) F. Sclafani et al. ANNALS OF ONCOLOGY
- KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy
- (2016) Oliver S. Chow et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution
- (2016) Ryutaro Uchi et al. PLoS Genetics
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Heterogeneity of KRAS Mutation Status in Rectal Cancer
- (2016) Peter Jo et al. PLoS One
- BRAFcodons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
- (2015) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- A Big Bang model of human colorectal tumor growth
- (2015) Andrea Sottoriva et al. NATURE GENETICS
- Fc RIIa and Fc RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease
- (2014) F. Sclafani et al. CLINICAL CANCER RESEARCH
- RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial
- (2014) F. Sclafani et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial
- (2014) Deborah Schrag et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial
- (2014) Francesco Sclafani et al. JNCI-Journal of the National Cancer Institute
- Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma
- (2013) Marjun P. Duldulao et al. ANNALS OF SURGICAL ONCOLOGY
- Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
- (2013) Olfa Derbel et al. BMC CANCER
- Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge
- (2013) S.M.E. Engelen et al. EUROPEAN JOURNAL OF CANCER
- KRASmutations andCDKN2Apromoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer
- (2013) Maija R. J. Kohonen-Corish et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
- (2013) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
- (2012) Alice Dewdney et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
- (2012) Florence Boissière-Michot et al. MODERN PATHOLOGY
- P53 Status as a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal Cancer
- (2012) Min-Bin Chen et al. PLoS One
- Does Neoadjuvant Therapy Alter KRAS and/or MSI Results in Rectal Adenocarcinoma Testing?
- (2011) Sarah L. Ondrejka et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer
- (2011) Julio Garcia-Aguilar et al. ANNALS OF SURGERY
- Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone
- (2011) Fiona G.M Taylor et al. ANNALS OF SURGERY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnetic Resonance Imaging–Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience
- (2011) Uday B. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Diagnosis of Response to Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer
- (2011) Zhenbin Chen et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy
- (2011) Janine M Davies et al. Radiation Oncology
- Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
- (2010) C Bengala et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial
- (2010) Yu Jo Chua et al. LANCET ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
- (2009) Y. He et al. CLINICAL CANCER RESEARCH
- Molecular Genetic Changes Associated With Colorectal Carcinogenesis Are Not Prognostic for Tumor Regression Following Preoperative Chemoradiation of Rectal Carcinoma
- (2009) N. Peter Zauber et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
- (2009) Jochen Gaedcke et al. RADIOTHERAPY AND ONCOLOGY
- The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers
- (2007) Lennart Blomqvist et al. ACTA ONCOLOGICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started